Technical Analysis for ORGS - Orgenesis Inc.

Grade Last Price % Change Price Change
D 5.06 14.74% 0.65
ORGS closed up 14.74 percent on Friday, May 14, 2021, on 53 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical ORGS trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 14.74%
Lower Bollinger Band Walk Weakness 14.74%
New 52 Week Low Weakness 14.74%
Lower Bollinger Band Touch Weakness 14.74%
Oversold Stochastic Weakness 14.74%
New 52 Week Closing Low Bearish 20.76%
Older End-of-Day Signals for ORGS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR 3 days ago
Rose Above 20 DMA 3 days ago
Up 10% 3 days ago
20 DMA Resistance 3 days ago
Rose Above 10 DMA 3 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Orgenesis Inc. Description

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Development Diabetes Stem Cells Endocrine System Insulin Cell Therapy Hormones Regenerative Medicine Contract Manufacturing Contract Manufacturing Services Peptide Hormones I Diabetes Medicinal Product Assay Development Services Diabetes Mellitus Type 1 Manufacturing Practice Medicinal Products

Is ORGS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.3
52 Week Low 4.145
Average Volume 533,832
200-Day Moving Average 5.47
50-Day Moving Average 5.75
20-Day Moving Average 4.84
10-Day Moving Average 4.70
Average True Range 0.52
ADX 25.18
+DI 26.69
-DI 16.18
Chandelier Exit (Long, 3 ATRs ) 4.90
Chandelier Exit (Short, 3 ATRs ) 5.71
Upper Bollinger Band 5.51
Lower Bollinger Band 4.17
Percent B (%b) 0.67
BandWidth 27.72
MACD Line -0.26
MACD Signal Line -0.31
MACD Histogram 0.0489
Fundamentals Value
Market Cap 122.23 Million
Num Shares 24.2 Million
EPS 2.35
Price-to-Earnings (P/E) Ratio 2.16
Price-to-Sales 6.64
Price-to-Book 1.38
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.08
Resistance 3 (R3) 5.98 5.54 5.91
Resistance 2 (R2) 5.54 5.28 5.59 5.85
Resistance 1 (R1) 5.30 5.12 5.42 5.40 5.80
Pivot Point 4.86 4.86 4.92 4.91 4.86
Support 1 (S1) 4.62 4.60 4.74 4.72 4.32
Support 2 (S2) 4.18 4.44 4.23 4.27
Support 3 (S3) 3.94 4.18 4.21
Support 4 (S4) 4.04